Company Overview and News

11
PBYI / Puma Biotechnology Inc. null

2018-06-14 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0S(# @;V)J#3P\+TQI;F5A
PBYI

17
PBYI / Puma Biotechnology Inc. FORM 8-K (Current Report)

2018-06-13 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
PBYI

14
PBYI / Puma Biotechnology Inc. FORM 8-K (Current Report)

2018-06-12 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
PBYI

13
Puma Biotechnology Looks Appealing As NERLYNX Concerns Overshadow Optimism

2018-06-11 seekingalpha
Investors in Puma Biotechnology have "enjoyed" a real roller-coaster ride in recent years; currently at a low point.
PBYI

12
PBYI / Puma Biotechnology Inc. 8-K (Current Report)

2018-06-04 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
PBYI

161
Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date

2018-05-11 seekingalpha
Eli Lilly (NYSE:LLY) has agreed to acquire ARMO BioSciences for $1.6bn ($50/share) in cash. This is almost a 40% premium to ARMO’s previous closing price of $29.82. It is currently trading at $49.80. The transaction will close this quarter, helping Lilly bolster its oncology unit.
ZIOP ARMO OPK EXEL PBYI CAH LLY AKCA CHRS

15
PBYI / Puma Biotechnology Inc. 10-Q (Quarterly Report)

2018-05-10 sec.gov
pbyi-10q_20180331.htm
PBYI

16
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down

2018-05-10 zacks
Puma Biotechnology, Inc. (PBYI - Free Report) reported a loss of 65 cents for the first-quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 75 cents and the year-ago loss of $1.97.
LGNZZ LGND LGNYZ PBYI LGNXZ PTGX LGNDZ

11
Puma Biotechnology, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2018 Q1 earnings call.
PBYI

12
Puma Biotechnology (PBYI) Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good afternoon. My name is Rob, and I'll be your conference call operator today. At this time, all participants are in a listen-only mode. After the speakers' formal remarks, there will be a question-and-answer session. As a reminder, this call is being recorded.
PBYI

11
PBYI / Puma Biotechnology Inc. 8-K (Current Report)

2018-05-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
PBYI

37
Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?

2018-05-07 zacks
Puma Biotechnology, Inc. (PBYI - Free Report) is scheduled to report first-quarter results on May 9 after market close.
EPZM KERX PBYI ADVM URBN

108
Adverum Biotechnologies Announces Leadership Changes

2018-05-03 globenewswire
MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced that the board of directors and Amber Salzman, Ph.D., president and chief executive officer and director, made a mutual determination that Dr. Salzman step down from these roles, effective May 3, 2018.
SNSS REGN EDIT PRTK NVS PBYI ADVM

12
PBYI / Puma Biotechnology Inc. DEF 14A

2018-04-30 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PBYI

15
PBYI / Puma Biotechnology Inc. DEFA14A

2018-04-30 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PBYI

PBYI: Puma Biotechnology Analysis and Research Report

2018-03-12 - Asif

Company Overview Puma Biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-license the global development and commercialization rights to three drug candidates – PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor, or TKI, that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, Puma Biotechnology is primarily focused on the U.S. commercialization of NERLYNX (neratinib), its first U.S. Food and Drug Administration, or FDA, approved product, and on the further development of the oral version of neratinib for additional indications in the treatment of HER2-positive breast cancer. The company believe neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types tha...

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 74587V107